KV agrees to FDA plan for resuming work

KV Pharmaceuticals said it has entered a consent decree with the FDA that provides for KV's return to manufacturing and distribution of its products, provided it satisfies a series of requirements. As you know, KV stopped making products in January and cut its workforce in half last month. Release

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.